Evidence map›Paper›PMID 27542345›Full record

ArticleBipolar disorders2016

Gene-specific DNA methylation may mediate atypical antipsychotic-induced insulin resistance.

Kyle J Burghardt, Jacyln M Goodrich, Dana C Dolinoy, Vicki L Ellingrod

Open access · bronzeAbstract read
In one paragraph

Article in Bipolar disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 4 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Skeletal muscle DNA methylation modifications and psychopharmacologic treatment in bipolar disorder.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2019
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Kyle J BurghardtDepartment of Pharmacy Practice, Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA.
Jacyln M GoodrichDepartment of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Dana C DolinoyDepartment of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Vicki L EllingrodDepartment of Clinical, Social, and Administrative Sciences, University of Michigan, College of Pharmacy, Ann Arbor, MI, USA.
University of Michigan–Ann Arbor · USMichigan Medicine · USWayne State University · US

Funding

MICHIGAN INSTITUTE FOR CLINICAL AND HEALTH RESEARCH (MICHR) (UL1): (BPCA)UL1RR024986 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHANLEY, THOMAS P. · 2007 to 2011
$51.2M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Strategic Vision & Impact on Environmental HealthP30ES017885 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Dana Dolinoy · 2011 to 2026
$21.3M
Research BaseP30DK092926 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARY ELLEN MICHELE HEISLER, ADESUWA B OLOMU · 2011 to 2026
$10.0M
Folate Pharmacogenomics and Risk of Atypical Antipsychtoic Metabolic Side EffectsR01MH082784 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ELLINGROD, VICKI L · 2008 to 2017
$4.0M
NCATS NIH HHS UL1 TR000433NCRR NIH HHS UL1 RR024986NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK092926NIEHS NIH HHS P30 ES017885NIMH NIH HHS R01 MH082784
6 · The paper itself

Abstract

objectivesAtypical antipsychotics (AAPs) carry a significant risk of cardiometabolic side effects, including insulin resistance. It is thought that the insulin resistance resulting from the use of AAPs may be associated with changes in DNA methylation. We aimed to identify and validate a candidate gene associated with AAP-induced insulin resistance by using a multi-step approach that included an epigenome-wide association study (EWAS) and validation with site-specific methylation and metabolomics data.

methodsSubjects with bipolar disorder treated with AAPs or lithium monotherapy were recruited for a cross-sectional visit to analyze peripheral blood DNA methylation and insulin resistance. Epigenome-wide DNA methylation was analyzed in a discovery sample (n = 48) using the Illumina 450K BeadChip. Validation analyses of the epigenome-wide findings occurred in a separate sample (n = 72) using site-specific methylation with pyrosequencing and untargeted metabolomics data. Regression analyses were conducted controlling for known confounders in all analyses and a mediation analysis was performed to investigate if AAP-induced insulin resistance occurs through changes in DNA methylation.

resultsA differentially methylated probe associated with insulin resistance was discovered and validated in the fatty acyl CoA reductase 2 (FAR2) gene of chromosome 12. Functional associations of this DNA methylation site with untargeted phospholipid-related metabolites were also detected. Our results identified a mediating effect of this FAR2 methylation site on AAP-induced insulin resistance.

conclusionsGoing forward, prospective, longitudinal studies assessing comprehensive changes in FAR2 DNA methylation, expression, and lipid metabolism before and after AAP treatment are required to assess its potential role in the development of insulin resistance.

Indexed as

Antipsychotic AgentsAdultAldehyde OxidoreductasesBipolar DisorderDNA MethylationEpigenesis, GeneticFemaleGenome-Wide Association StudyHumansInsulin ResistanceMalePharmacogeneticsProspective StudiesReproducibility of ResultsAldehyde OxidoreductasesAntipsychotic AgentsFAR2 protein, humanantipsychoticsbipolar disorderinsulinmediationmethylation

Identifiers

PMID27542345
PMCPMC5322870
OpenAlexW2515414411

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.